Health Tidings Mergers & AcquisitionsBiogen Licenses Alloy AntiClastic ASO Technology Biogen Licenses Alloy AntiClastic ASO Technology Read Post »
Health Tidings Mergers & AcquisitionsAC Immune Expands Tau Program Under Lilly Agreement AC Immune Expands Tau Program Under Lilly Agreement Read Post »
Mergers & AcquisitionsGilead Bolsters ADC Strategy with Tubulis Acquisition Worth Up to $5B Gilead Bolsters ADC Strategy with Tubulis Acquisition Worth Up to $5B Read Post »
Health Tidings Mergers & AcquisitionsNeurocrine to Acquire Soleno, Strengthening Rare Disease Portfolio with VYK... Neurocrine to Acquire Soleno, Strengthening Rare Disease Portfolio with VYK... Read Post »
Mergers & AcquisitionsDenali Therapeutics Inc. Regains Full Rights to DNL593 After Takeda Pharmac... Denali Therapeutics Inc. Regains Full Rights to DNL593 After Takeda Pharmac... Read Post »
Health Tidings Mergers & AcquisitionsRegeneron Partners with TriNetX to Leverage 300 Million Patient Records for... Regeneron Partners with TriNetX to Leverage 300 Million Patient Records for... Read Post »
Mergers & AcquisitionsLupin Completes VISUfarma Acquisition, Expands European Ophthalmology Portf... Lupin Completes VISUfarma Acquisition, Expands European Ophthalmology Portf... Read Post »
Health Tidings Mergers & AcquisitionsZai Lab, Amgen Partner to Advance DLL3 Dual-Targeting Strategy in SCLC Zai Lab, Amgen Partner to Advance DLL3 Dual-Targeting Strategy in SCLC Read Post »
Mergers & AcquisitionsBioVersys Strikes Ansamycin Antibiotic Deal with Hackensack Meridian Health BioVersys Strikes Ansamycin Antibiotic Deal with Hackensack Meridian Health Read Post »
Mergers & AcquisitionsAxsome-Takeda Deal Brings Balipodect into Late-Stage CNS Development Axsome-Takeda Deal Brings Balipodect into Late-Stage CNS Development Read Post »
Health Tidings Mergers & AcquisitionsBiogen’s $5.6B Apellis Deal Boosts Immunology and Rare Disease Portfolio Biogen’s $5.6B Apellis Deal Boosts Immunology and Rare Disease Portfolio Read Post »
Health Tidings Mergers & AcquisitionsGalapagos – Gilead Finalize Ouro-Linked Deal to Advance Gamgertamig Galapagos – Gilead Finalize Ouro-Linked Deal to Advance Gamgertamig Read Post »
Mergers & AcquisitionsLilly to Acquire Centessa in $6.3B Deal, Expands Orexin Pipeline for Sleep ... Lilly to Acquire Centessa in $6.3B Deal, Expands Orexin Pipeline for Sleep ... Read Post »
Health Tidings Mergers & AcquisitionsAfter NVIDIA, Lilly Signs New AI Drug Discovery Deal with Insilico After NVIDIA, Lilly Signs New AI Drug Discovery Deal with Insilico Read Post »
Mergers & AcquisitionsNovartis to Acquire Excellergy for Up to $2 Billion, Adds Next-Generation A... Novartis to Acquire Excellergy for Up to $2 Billion, Adds Next-Generation A... Read Post »
Mergers & AcquisitionsOtsuka to Acquire Transcend Therapeutics in Up to $1.2B Deal to Advance PTS... Otsuka to Acquire Transcend Therapeutics in Up to $1.2B Deal to Advance PTS... Read Post »
Health Tidings Mergers & AcquisitionsBiogen Signs Deal with Alteogen to Develop Subcutaneous Versions of Two Bio... Biogen Signs Deal with Alteogen to Develop Subcutaneous Versions of Two Bio... Read Post »
Mergers & AcquisitionsJanux Targets 2026 TRACTr Updates, Announces BMS Collaboration Janux Targets 2026 TRACTr Updates, Announces BMS Collaboration Read Post »
Health Tidings Mergers & AcquisitionsMerck to Buy Terns, Strengthening CML Pipeline with TERN-701 Merck to Buy Terns, Strengthening CML Pipeline with TERN-701 Read Post »
Health Tidings Mergers & AcquisitionsAlnylam, Viz.ai Partner to Advance AI Detection of ATTR-CM Alnylam, Viz.ai Partner to Advance AI Detection of ATTR-CM Read Post »
Mergers & Acquisitions Policy & AcquisitionsGilead to Acquire Ouro Medicines for $1.7B; Galapagos in Talks to Partner o... Gilead to Acquire Ouro Medicines for $1.7B; Galapagos in Talks to Partner o... Read Post »
Mergers & AcquisitionsSanofi Inks Up to $1.23B Licensing Deal for Kali Therapeutics’ Autoimmune... Sanofi Inks Up to $1.23B Licensing Deal for Kali Therapeutics’ Autoimmune... Read Post »
Mergers & AcquisitionsSandoz Bets on $320B Biosimilar Opportunity with New Samsung Bioepis Partne... Sandoz Bets on $320B Biosimilar Opportunity with New Samsung Bioepis Partne... Read Post »
